Molecular Characterization of TMPRSS2-ERG Gene Fusion in the NCI-H660 Prostate Cancer Cell Line: a New Perspective for an Old Model

Overview

Journal Neoplasia

Publisher Elsevier

Specialty Oncology

Date 2007 Apr 3

PMID 17401460

Citations 77

Authors

Kirsten D Mertz

Sunita R Setlur

Saravana M Dhanasekaran

Francesca Demichelis

Sven Perner

Scott Tomlins

Joelle Tchinda

Bharathi Laxman

Robert L Vessella

Rameen Beroukhim

Charles Lee

Arul M Chinnaiyan

Mark A Rubin

Affiliations

Soon will be listed here.

Abstract

Recent studies have established that a significant fraction of prostate cancers harbor a signature gene fusion between the 5' region of androgen-regulated TMPRSS2 and an ETS family transcription factor, most commonly ERG. Studies on the molecular mechanisms and functional consequences of this important chromosomal rearrangement are currently limited to the VCaP cell line derived from a vertebral bone metastasis of a hormone-refractory prostate tumor. Here we report on the NCI-H660 cell line, derived from a metastatic site of an extrapulmonary small cell carcinoma arising from the prostate. NCI-H660 harbors TMPRSS2-ERG fusion with a homozygous intronic deletion between TMPRSS2 and ERG. We demonstrate this by real-time quantitative polymerase chain reaction, a two-stage dual-color interphase fluorescence in situ hybridization (FISH) assay testing for TMPRSS2 and ERG break-aparts, and single-nucleotide polymorphism oligonucleotide arrays. The deletion is consistent with the common intronic deletion found on chromosome 21q22.2-3 in human prostate cancer samples. We demonstrate the physical juxtaposition of TMPRSS2 and ERG on the DNA level by fiber FISH. The androgen receptor-negative NCI-H660 cell line expresses ERG in an androgen-independent fashion. This in vitro model system has the potential to provide important pathobiologic insights into TMPRSS2-ERG fusion prostate cancer.

Citing Articles

A highly sensitive screening system to evaluate the reversibility of neuroendocrine prostate cancer to prostate adenocarcinoma.

Fukui T, Okasho K, Okuno Y, Fujiwara M, Hikami K, Fukunaga A Cancer Med. 2025; 14(5):e70047.

PMID: 40013333 PMC: 11865886. DOI: 10.1002/cam4.70047.

AR and YAP crosstalk: impacts on therapeutic strategies in prostate cancer.

Zheng G, Yan Z, Zou J, Zou X, Chai K, Zhang G Front Oncol. 2025; 15:1520808.

PMID: 39963114 PMC: 11830605. DOI: 10.3389/fonc.2025.1520808.

Understanding the function of Pax5 in development of docetaxel-resistant neuroendocrine-like prostate cancers.

Bhattacharya S, Harris H, Islam R, Bodas S, Polavaram N, Mishra J Cell Death Dis. 2024; 15(8):617.

PMID: 39183332 PMC: 11345443. DOI: 10.1038/s41419-024-06916-y.

ENO2, a Glycolytic Enzyme, Contributes to Prostate Cancer Metastasis: A Systematic Review of Literature.

Zhou Y, Zeng F, Richards G, Wang N Cancers (Basel). 2024; 16(14).

PMID: 39061144 PMC: 11274830. DOI: 10.3390/cancers16142503.

Understanding the role of Pax5 in development of taxane-resistant neuroendocrine like prostate cancers.

Dutta S, Bhattacharya S, Harris H, Islam R, Bodas S, Polavaram N Res Sq. 2024; .

PMID: 38168280 PMC: 10760218. DOI: 10.21203/rs.3.rs-3464475/v1.

References

Tomlins S, Mehra R, Rhodes D, Smith L, Roulston D, Helgeson B . TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 2006; 66(7):3396-400. DOI: 10.1158/0008-5472.CAN-06-0168. View

Tomlins S, Rhodes D, Perner S, Dhanasekaran S, Mehra R, Sun X . Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005; 310(5748):644-8. DOI: 10.1126/science.1117679. View

Perner S, Demichelis F, Beroukhim R, Schmidt F, Mosquera J, Setlur S . TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 2006; 66(17):8337-41. DOI: 10.1158/0008-5472.CAN-06-1482. View

Wang J, Cai Y, Ren C, Ittmann M . Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res. 2006; 66(17):8347-51. DOI: 10.1158/0008-5472.CAN-06-1966. View

Hermans K, van Marion R, van Dekken H, Jenster G, van Weerden W, Trapman J . TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res. 2006; 66(22):10658-63. DOI: 10.1158/0008-5472.CAN-06-1871. View

Clark J, Merson S, Jhavar S, Flohr P, Edwards S, Foster C . Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene. 2006; 26(18):2667-73. DOI: 10.1038/sj.onc.1210070. View

Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur S . TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007; 26(31):4596-9. DOI: 10.1038/sj.onc.1210237. View

Rubin M, Putzi M, Mucci N, Smith D, Wojno K, Korenchuk S . Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res. 2000; 6(3):1038-45. View

Li C, Wong W . Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci U S A. 2001; 98(1):31-6. PMC: 14539. DOI: 10.1073/pnas.98.1.31. View

10.

Korenchuk S, Lehr J, McLean L, Lee Y, Whitney S, Vessella R . VCaP, a cell-based model system of human prostate cancer. In Vivo. 2001; 15(2):163-8. View

11.

Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A . Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002; 3(7):RESEARCH0034. PMC: 126239. DOI: 10.1186/gb-2002-3-7-research0034. View

12.

Van Bokhoven A, Varella-Garcia M, Korch C, Johannes W, Smith E, Miller H . Molecular characterization of human prostate carcinoma cell lines. Prostate. 2003; 57(3):205-25. DOI: 10.1002/pros.10290. View

13.

Kennedy G, Matsuzaki H, Dong S, Liu W, Huang J, Liu G . Large-scale genotyping of complex DNA. Nat Biotechnol. 2003; 21(10):1233-7. DOI: 10.1038/nbt869. View

14.

Lin M, Wei L, Sellers W, Lieberfarb M, Wong W, Li C . dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics. 2004; 20(8):1233-40. DOI: 10.1093/bioinformatics/bth069. View

15.

Iafrate A, Feuk L, Rivera M, Listewnik M, Donahoe P, Qi Y . Detection of large-scale variation in the human genome. Nat Genet. 2004; 36(9):949-51. DOI: 10.1038/ng1416. View

16.

Carney D, Gazdar A, Bepler G, Guccion J, Marangos P, Moody T . Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 1985; 45(6):2913-23. View

17.

Johnson B, Whang-Peng J, Naylor S, Zbar B, Brauch H, Lee E . Retention of chromosome 3 in extrapulmonary small cell cancer shown by molecular and cytogenetic studies. J Natl Cancer Inst. 1989; 81(16):1223-8. DOI: 10.1093/jnci/81.16.1223. View

18.

Lai S, Brauch H, Knutsen T, Johnson B, Nau M, Mitsudomi T . Molecular genetic characterization of neuroendocrine lung cancer cell lines. Anticancer Res. 1995; 15(2):225-32. View

19.

Lin B, Ferguson C, White J, Wang S, Vessella R, True L . Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res. 1999; 59(17):4180-4. View

20.

Shah R, Mehra R, Chinnaiyan A, Shen R, Ghosh D, Zhou M . Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res. 2004; 64(24):9209-16. DOI: 10.1158/0008-5472.CAN-04-2442. View